Medical technology company Chordate Medical has developed Kinetic Oscillation Stimulation (KOS), a drug-free treatment method for chronic migraine. The patient study PM007 shows that KOS provides a significant reduction in the number of headache days in patients suffering from chronic migraine.
Presentations at several conferences
Parts of the study results have previously been presented at, among others: American Headache Society's Congress in Austin, Texas and The German Migraine and Headache Society's congress in Berlin. In September, one of the study leaders, Dr. Hoffmann, King's College London, to present the results in a poster presentation at International Headache Congress (IHC) 2023, Seoul, South Korea.
International Headache Society
The congress is organized every two years by International Headache Society, an international organization based in the United Kingdom. IHS operates as a charitable organization and strives to raise awareness of headaches and promote research, education and the management of this distressing condition worldwide.
This year, the organization's congress will be held in Seoul, Korea, which is the first time the event has taken place in Asia since 2005.
CEO about the conference and other activities
Chordate Medical will also attend IHC 2023 as an exhibitor, providing an opportunity to introduce KOS and its benefits to leading experts and industry within the migraine field.
In addition to increased conference attendance during the fall, the company will continue its market introductions in countries such as Finland, Germany and the UK. In parallel, Chordate Medical's partners are working further on the approval processes in both the US and China. Last but not least, the company looks forward to publishing the results from the PM007 study in a scientific article. The study leaders have submitted a manuscript with complete study results to one of the three most prominent journals in the migraine field. Once the scientific article is approved and published, it will be a valuable resource for marketing and sales work.
BioStock contacted Chordate Medical's CEO Anders Weilandt to find out more about the activities during the fall.
Why is the International Headache Congress a good opportunity to present the KOS treatment method?
– IHC is THE international forum where the world's headache experts and industry meet. The scientific congress is of course the most important thing for the approximately 1000-2000 delegates, but the integrated industry exhibition also receives a lot of attention. For Chordate, a new player in the arena, it is an extra valuable opportunity to be seen and make contacts.
»The scientific congress is of course the most important thing for the approximately 1000-2000 delegates, but the integrated industrial exhibition also receives a lot of attention. For Chordate, which is a new player in the arena, it is an extra valuable opportunity to be seen and make contacts.«
In a press release you mention that there is great interest in the study and its results within the migraine field. Can you specify which parts of the results you think will arouse the most interest among the congress participants?
– Above all, it is the new opportunity to offer patients a well-functioning alternative that is drug-free, with a very favorable side effect profile and with long-lasting preventive effects. Such an alternative is in great demand.
– The second thing that arouses interest is that the treatment method is simple and easy to learn – this means that it can become a very accessible option that does not require the time of a specialist doctor.
» The treatment method is simple and easy to learn – this makes it a very accessible option that does not require the time of a specialist doctor.«
You have just announced that the manuscript for the scientific article has been submitted by the trial leaders, what does this mean for the company?
– It is a much-anticipated event that can now be marked as delivered after thorough analysis and writing work by the authors. The data material is extensive and in many parts very interesting. As I understand it, there has been some work in choosing what to include in this first article. It is not unlikely that further analysis may result in several articles on aspects other than those reported in this current article. Overall, it is very good that it is finished – and a good support for our marketing work when the article is approved for publication.
»It's simply full speed ahead that matters. We are in the early commercialization phase. In medtech, this always means dedicated work with long sales times before you see results. We know how and what we have to do to achieve our goals.«
Summer is coming to an end and the preparations for the fall have begun. How would you describe the phase that Chordate Medical is in right now?
– It's simply full speed ahead. We are in the early commercialization phase. In medtech, this always means dedicated work with long sales periods before you see results. We know how and what we have to do to achieve our goals.